Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NVCT vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVCT Captures Overall Composite Edge (48.4 HOLD vs 36.8 SELL), While BOLD Leads 3–1 on Growth & Valuation Pillars

NVCT Overall Winner 6-Pillar Tally: NVCT 1 – 3 BOLD (2 Tie) Matrix Metrics: NVCT 2 – 3 BOLD

As of Nov 20, 2026, Nuvectis Pharma, Inc. (NVCT) captures the overall head-to-head institutional edge over Boundless Bio, Inc. (BOLD) on higher Unified Composite conviction (48.4/100 HOLD vs. 36.8/100 SELL) after splitting the core matrix 2–3 (led by Growth & Scale), while BOLD wins 3–1 across the 6-pillar growth and valuation breakdown. NVCT trades at $19.39 (N/M Forward P/E, 0.0% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: NVCT earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. BOLD 36.8/100 SELL) and 0.71β · 80% Vol risk profile, whereas BOLD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 47.4); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVCT vs BOLD
NVCT NASDAQ Head-to-Head Winner
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.39
-2.27% 1D
Market Cap $682.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 80% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 34.0 Fund 49.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.47 · SMA50: $20.21
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (NVCT 1 – 3 BOLD)

Columns: Metric · NVCT · BOLD
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale NVCT
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $682.3M $56.2M
3. Profitability & Quality BOLD
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -67.0% -64.6%
4. Balance Sheet & Cash Flow BOLD
Cash Generation (TTM) -$40M -$48M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.68 Book/Sh · -67.0% ROE $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BOLD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 106.9% (16th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVCT (2) vs BOLD (3)
Institutional Metric NVCT BOLD Criterion Row Edge
Market Capitalization
Scale
$682.3M $56.2M Larger Scale NVCT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-67.0% -64.6% Higher ROE BOLD
52-Week Range Position
Momentum
58% ($6–$29) 62% ($1–$3) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
0.71β · 80% Vol -0.08β · 28% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite NVCT
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$40M ($3.68 Book/Sh · -67.0% ROE) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BOLD +2.26 pp
NVCT: -7.18% · BOLD: -4.92%
3M Horizon NVCT +2.85 pp
NVCT: -18.77% · BOLD: -21.62%
6M Horizon NVCT +26.23 pp
NVCT: +87.34% · BOLD: +61.11%
1Y Horizon NVCT +123.05 pp
NVCT: +224.79% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVCT vs BOLD. Trailing 12-month operating profitability (NVCT 0.0% vs BOLD 0.0%) and valuation multiples (NVCT N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NVCT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-67.0% · N/M
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVCT BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 106.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact NVCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVCT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $682.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NVCT vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, Nuvectis Pharma, Inc. (NVCT) captures the overall head-to-head institutional edge over Boundless Bio, Inc. (BOLD) on higher Unified Composite conviction (48.4/100 HOLD vs. 36.8/100 SELL) after splitting the core matrix 2–3 (led by Growth & Scale), while BOLD wins 3–1 across the 6-pillar growth and valuation breakdown. NVCT trades at $19.39 (N/M Forward P/E, 0.0% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NVCT earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. BOLD 36.8/100 SELL) and 0.71β · 80% Vol risk profile, whereas BOLD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 47.4); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NVCT leads the Growth & Scale pillar: NVCT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NVCT generates N/A in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, NVCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

NVCT and BOLD trade at balanced relative valuation multiples. NVCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVCT (-67.0% ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NVCT carries 106.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.71β · 80% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.